Bayer announced today the United States (U.S.) Food and Drug Administration (FDA) has approved KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction (MI) and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
The weather turns cold in winter. Many diseases are more likely to occur at this time. They enter the high incidence season of myocardial infarction, cerebral infarction and pulmonary infarction. The treatment of these “stems” can not rely on luck. How to prevent and treat them? Come and see~